Providing updates on objectives, Pharmacyte Biotech Inc (OTCMKTS:PMCB) reported that it will form an IND team to design the IND and assess it before being officially filed with the regulatory authorities. He company’s IND Team will include a Project Manager, a Medical Officer, a Statistician, a Chemistry, Controls and Manufacturing Expert, a Pharmacologist, a Pharmakineticist, a Toxicologist, an Interventional Radiologist, a Radiologist, and a Regulatory Affairs person.
Pharmacyte also reported that with pivotal input from its team of oncologists, the plan of its clinical study will be finalized with an objective of formulating the highest probability of developing encouraging data during the study that could result in marketing approval of pancreatic cancer treatment.
In last trading session, the stock price of Pharmacyte declined more than 3% to close the trading session at $0.0878. The decline came at a share volume of 1.85 million compared to average monthly share volume of 1.41 million. After the recent drop, the market cap of company stands at 65.27 million.
Nutra Pharma Corp. (OTCMKTS:NPHC) received Orphan Drug designation for RPI-78M targeting Multiple Sclerosis in children. The company operates as a biotechnology firm marketing Nyloxin® and Pet Pain-Away, and formulating drugs for the treatment of Adrenomyeloneuropathy, Multiple Sclerosis and Human Immunodeficiency Virus.
The Company specializes in the licensing, acquisition and commercialization of pharmaceutical products for the management of neurological disorders, infectious diseases, cancer and autoimmune.
Uluru Inc (OTCMKTS:ULUR) reported 2Q2015 results wherein it revealed that Research and development expenses surged to $219,000 in 2Q from $184,000 in the same quarter, a year earlier. The R&D expenses included $19,000 in share-based compensation compared to $5,000 in share-based compensation in second quarter of 2014.
This increase in research and development expenses can be attributed to $16,000 jump in scientific compensation associated with share-based compensation and increased direct research costs related to Altrazeal®.
